Critical-minerals stocks need contracts, not headlines
Washington’s critical-minerals push can create demand, but it cannot turn every domestic explorer into a commercial producer. We favor companies showing processing output, customer commitments, and financing rather than policy-fueled optionality alone.
The latest defense-critical-minerals push is real industrial policy, but retail is pricing it as if policy attention were already revenue. That is the wrong scoreboard. The durable winners will be the companies that can process material, fulfill a customer contract, and finance the next stage of expansion; the rest remain exposed to permitting, commissioning, dilution, and execution risk. Within this group, MP has the clearest operating evidence, while USAR, UAMY, and each offer a different version of a story that still needs to become a business.
The distinction matters because the market is rewarding strategic narratives far faster than it is rewarding cash generation. Current market data puts MP at roughly 22 times sales, compared with about 203 times for USAR and more than 700 times for CRML. Those multiples are not proof that any one company is doomed, but they show how little room there is for delays when investors are capitalizing future domestic supply chains today. A defense designation can improve the odds of funding and customer access; it does not eliminate the basic requirement to build and operate profitable capacity.
MP is the closest thing in this basket to an established operating platform. In the first quarter of 2026, it reported record rare-earth oxide production of 12,983 metric tons, $36.6 million of adjusted EBITDA, and only $1.9 million of net cash used in operating activities. More important for this debate, it has a $500 million Apple supply agreement for recycled rare-earth magnets and prior Pentagon backing. That combination of production, a major customer, and government support gives MP commercial visibility that a press release about strategic importance cannot replicate. The caveat is valuation and profitability: MP still carried a negative 20.5% net margin in the supplied market data. It is a real business, not a risk-free one.
USAR illustrates why financing should be treated as necessary but not sufficient. The company had about $1.75 billion in cash after a $1.5 billion PIPE and a Commerce/CHIPS package of up to $1.6 billion. That is meaningful balance-sheet support for a capital-intensive buildout, and bulls are right to argue that government backing can accelerate a strategic industry that private capital might otherwise undersupply. But USAR has also said its U.S. operations have not yet generated revenue from neo-magnet manufacturing or critical-mineral production. Cash can buy time, equipment, and engineering capacity; it cannot substitute for commercial output. With no U.S. revenue yet and a sales multiple above 200, the stock is largely a bet that execution will follow the financing.
UAMY has a stronger near-term commercial anchor than a pre-revenue developer, but its scale needs to be kept in view. It recognized $2.7 million of revenue related to its Defense Logistics Agency contract in the first quarter of 2026, while full-year 2025 antimony revenue rose 219% to $35.4 million and gross margin improved to 25%. Those are legitimate signs of traction, and the contract matters more than a generic announcement because it ties demand to an actual customer. Still, the absolute revenue base remains small relative to the roughly $789 million market capitalization in the supplied data, and the company remains loss-making. UAMY may be a credible niche supplier, but it is not yet evidence that every defense-critical-minerals name can scale on policy momentum alone.
CRML is the clearest test of whether investors are confusing project optionality with operating scale. It has announced a $60 million private placement, an earlier $35 million PIPE, a 15-year binding offtake agreement with REalloys, and Phase 1 nameplate capacity of up to 15,000 metric tons of rare-earth concentrate annually. The offtake and financing are meaningful improvements over a pure exploration story. Yet the asset remains development-stage, and the capacity is a plan to be commissioned rather than production already flowing. That distinction is especially important beside CRML’s roughly 701-times sales multiple and negative 20,540.5% net margin in the supplied market data. A long-term contract can validate a project; it does not remove construction and commissioning risk.
The strongest bull case is that Washington is moving from speeches to enforcement. New defense supply-chain rules are pushing contractors to eliminate China-linked critical-mineral inputs, while government packages for companies such as USAR and MP show a willingness to underwrite domestic capacity. We agree that this can create forced demand and improve the economics of projects that reach production. But the timing cuts both ways: industry reporting indicates that even a Pentagon-backed refinery expansion could take 14 to 18 months to build, while contractors face a January 1, 2027 deadline to stop sourcing certain materials from China. Urgency may increase the value of qualified suppliers, but it also exposes the gap between announcing capacity and delivering it.
The contrarian trade is not to dismiss the critical-minerals theme; it is to stop treating every ticker as an equal beneficiary. We would put the greatest weight on verified production, binding customer commitments, and a financing plan that can survive delays, which leaves MP with the strongest current evidence and UAMY with tangible but limited contract traction. USAR has the capital to become important, while CRML has offtake and project potential, but both still need to convert funding and agreements into operating revenue.
What would change our view is simple: sustained commercial output, repeatable margins, and customer receipts that make the policy premium measurable rather than aspirational. Until then, the headline trade remains vulnerable to the first missed milestone, financing need, or construction delay.
Our take, not advice. This is opinion commentary — informational only, not personalized investment recommendations. Markets carry risk. Do your own research and consider your own situation before any trade.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
